1h Free Analyst Time
Speak directly to the analyst to clarify any post sales queries you may have.
Antisense oligonucleotide therapies are reshaping the management of transthyretin amyloidosis through a targeted, gene-modulating approach. This market report provides senior executives with a strategic, data-driven analysis of emerging trends, regional dynamics, and actionable recommendations to guide high-stakes decision-making in this evolving therapeutic space.
Market Snapshot: Antisense Oligonucleotide Therapeutics Market
The antisense oligonucleotide therapeutics market is experiencing strong momentum, driven by advancements in molecular design, increasing clinical adoption, and a changing global regulatory landscape. Key therapies such as Eplontersen and Inotersen are progressing from niche treatments to integral components of amyloidosis care, supported by robust infrastructure in major regions and a shift toward earlier-stage intervention. Forward-looking regulatory milestones and combined real-world evidence have positioned this segment for continued evolution and expanded access.
Scope & Segmentation
This report delivers a thorough investigation into the current and future outlook of antisense oligonucleotide therapies within transthyretin amyloidosis management. The segmentation covers all relevant market drivers and stakeholder touchpoints, providing deep visibility across:
- Drug Types: Eplontersen, Inotersen
- Distribution Channels: Hospital pharmacy (private, public), online pharmacy, specialty pharmacy
- End Users: Clinics (general, specialist), home healthcare (self-administration, visiting nurse services), hospitals (private, public), nursing homes (assisted living, long-term care facilities)
- Route of Administration: Intravenous infusion, oral administration, subcutaneous injection
- Patient Types: Familial, wild type
- Therapy Lines: First, second, third line
- Disease Stages: Early, late, pre-symptomatic
- Regions Analyzed: Americas (United States—California, Texas, New York, Florida, Illinois, Pennsylvania, Ohio; Canada, Mexico, Brazil, Argentina), Europe, Middle East & Africa (including United Kingdom, Germany, France, and others), Asia-Pacific (China, India, Japan, Australia, South Korea, etc.)
- Companies Profiled: Ionis Pharmaceuticals, Inc., Akcea Therapeutics, Inc.
Key Takeaways: Strategic Insights for Decision-Makers
- Antisense oligonucleotide therapies now address genetic drivers of amyloidosis, enabling earlier intervention and changing disease trajectories.
- Next-generation chemistries and advances in targeted delivery have enhanced both efficacy and safety, overcoming prior clinical challenges.
- Improvements in biomarker development and diagnostic imaging foster earlier patient identification, allowing pre-symptomatic and early stage deployment of therapies.
- Progress in segmentation allows for tailored clinical protocols, ranging from differentiation by drug type to personalized dosing based on therapy line and disease stage.
- Strategic collaborations, diverse real-world evidence initiatives, and competitive patent positioning are shaping the competitive environment and accelerating innovation cycles.
- Regional market entry requires alignment with reimbursement pathways, local regulatory frameworks, and emerging provider-payer-consortium structures.
Tariff Impact: U.S. 2025 Policy Changes
The U.S. introduction of new tariffs for 2025 is directly affecting the cost structure and accessibility of antisense oligonucleotide therapies. Companies are responding with supply chain diversification, revision of manufacturer contracts, and increased engagement with domestic contract manufacturing. Some firms absorb higher costs to protect patient affordability, while others adjust pricing. Payers and providers are evolving reimbursement models to match altered expense profiles, underscoring the interplay between global trade policy and therapeutic deployment.
Methodology & Data Sources
This analysis integrates peer-reviewed literature, patent filings, clinical trial and regulatory databases, and public policy documents with primary interviews involving clinicians, payers, patient advocates, and manufacturing experts. Rigorous triangulation and systematic data validation checkpoints ensure accuracy, reliability, and transparency throughout the research process.
Why This Report Matters
- Offers strategic clarity for senior leaders evaluating expansion, partnership, or product lifecycle management opportunities in a dynamic market.
- Equips stakeholders with actionable insights on technology advances, geographic opportunities, segmentation strategies, and evolving access barriers.
- Enables more confident, evidence-based decision-making amid shifting policy, competitive, and technological conditions.
Conclusion
As antisense oligonucleotide therapies reorient the approach to transthyretin amyloidosis, organizations that adapt early to complex market forces and policy shifts will secure sustainable growth. This report delivers the knowledge needed for confident strategic positioning in a rapidly progressing therapeutic domain.
This product will be delivered within 1-3 business days.
Table of Contents
1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
4.2. Market Sizing & Forecasting
5. Market Dynamics
5.1. Evaluating real-world comparative effectiveness of antisense oligonucleotides versus tafamidis in ATTR management
5.2. Advances in ligand conjugation technologies to enhance cardiac delivery of antisense oligonucleotides for ATTR
5.3. Regulatory pathways and accelerated approval trends for next generation antisense oligonucleotide therapies in ATTR
5.4. Impact of emerging gene editing and RNA interference platforms on the competitive landscape of ATTR antisense drugs
5.5. Patient stratification strategies using genetic and biomarker profiling for optimized antisense oligonucleotide dosing in ATTR
5.6. Cost-effectiveness analyses and reimbursement challenges for high-cost antisense oligomer therapies in hereditary ATTR
5.7. Manufacturing scale-up innovations reducing supply chain constraints for antisense oligonucleotides in ATTR treatment
5.8. Longitudinal safety data and immunogenicity monitoring in chronic administration of antisense oligonucleotides for ATTR
5.2. Advances in ligand conjugation technologies to enhance cardiac delivery of antisense oligonucleotides for ATTR
5.3. Regulatory pathways and accelerated approval trends for next generation antisense oligonucleotide therapies in ATTR
5.4. Impact of emerging gene editing and RNA interference platforms on the competitive landscape of ATTR antisense drugs
5.5. Patient stratification strategies using genetic and biomarker profiling for optimized antisense oligonucleotide dosing in ATTR
5.6. Cost-effectiveness analyses and reimbursement challenges for high-cost antisense oligomer therapies in hereditary ATTR
5.7. Manufacturing scale-up innovations reducing supply chain constraints for antisense oligonucleotides in ATTR treatment
5.8. Longitudinal safety data and immunogenicity monitoring in chronic administration of antisense oligonucleotides for ATTR
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
6.2. PESTLE Analysis
8. Antisense Oligonucleotides Drugs for ATTR Market, by Drug Type
8.1. Introduction
8.2. Eplontersen
8.3. Inotersen
8.2. Eplontersen
8.3. Inotersen
9. Antisense Oligonucleotides Drugs for ATTR Market, by Distribution Channel
9.1. Introduction
9.2. Hospital Pharmacy
9.2.1. Private Hospital Pharmacy
9.2.2. Public Hospital Pharmacy
9.3. Online Pharmacy
9.4. Specialty Pharmacy
9.2. Hospital Pharmacy
9.2.1. Private Hospital Pharmacy
9.2.2. Public Hospital Pharmacy
9.3. Online Pharmacy
9.4. Specialty Pharmacy
10. Antisense Oligonucleotides Drugs for ATTR Market, by End User
10.1. Introduction
10.2. Clinics
10.2.1. General Clinics
10.2.2. Specialist Clinics
10.3. Home Healthcare
10.3.1. Self Administration
10.3.2. Visiting Nurse Services
10.4. Hospitals
10.4.1. Private Hospitals
10.4.2. Public Hospitals
10.5. Nursing Homes
10.5.1. Assisted Living
10.5.2. Long Term Care Facilities
10.2. Clinics
10.2.1. General Clinics
10.2.2. Specialist Clinics
10.3. Home Healthcare
10.3.1. Self Administration
10.3.2. Visiting Nurse Services
10.4. Hospitals
10.4.1. Private Hospitals
10.4.2. Public Hospitals
10.5. Nursing Homes
10.5.1. Assisted Living
10.5.2. Long Term Care Facilities
11. Antisense Oligonucleotides Drugs for ATTR Market, by Route Of Administration
11.1. Introduction
11.2. Intravenous Infusion
11.3. Oral Administration
11.4. Subcutaneous Injection
11.2. Intravenous Infusion
11.3. Oral Administration
11.4. Subcutaneous Injection
12. Antisense Oligonucleotides Drugs for ATTR Market, by Patient Type
12.1. Introduction
12.2. Familial
12.3. Wild Type
12.2. Familial
12.3. Wild Type
13. Antisense Oligonucleotides Drugs for ATTR Market, by Therapy Line
13.1. Introduction
13.2. First Line
13.3. Second Line
13.4. Third Line
13.2. First Line
13.3. Second Line
13.4. Third Line
14. Antisense Oligonucleotides Drugs for ATTR Market, by Disease Stage
14.1. Introduction
14.2. Early Stage
14.3. Late Stage
14.4. Pre Symptomatic
14.2. Early Stage
14.3. Late Stage
14.4. Pre Symptomatic
15. Americas Antisense Oligonucleotides Drugs for ATTR Market
15.1. Introduction
15.2. United States
15.3. Canada
15.4. Mexico
15.5. Brazil
15.6. Argentina
15.2. United States
15.3. Canada
15.4. Mexico
15.5. Brazil
15.6. Argentina
16. Europe, Middle East & Africa Antisense Oligonucleotides Drugs for ATTR Market
16.1. Introduction
16.2. United Kingdom
16.3. Germany
16.4. France
16.5. Russia
16.6. Italy
16.7. Spain
16.8. United Arab Emirates
16.9. Saudi Arabia
16.10. South Africa
16.11. Denmark
16.12. Netherlands
16.13. Qatar
16.14. Finland
16.15. Sweden
16.16. Nigeria
16.17. Egypt
16.18. Turkey
16.19. Israel
16.20. Norway
16.21. Poland
16.22. Switzerland
16.2. United Kingdom
16.3. Germany
16.4. France
16.5. Russia
16.6. Italy
16.7. Spain
16.8. United Arab Emirates
16.9. Saudi Arabia
16.10. South Africa
16.11. Denmark
16.12. Netherlands
16.13. Qatar
16.14. Finland
16.15. Sweden
16.16. Nigeria
16.17. Egypt
16.18. Turkey
16.19. Israel
16.20. Norway
16.21. Poland
16.22. Switzerland
17. Asia-Pacific Antisense Oligonucleotides Drugs for ATTR Market
17.1. Introduction
17.2. China
17.3. India
17.4. Japan
17.5. Australia
17.6. South Korea
17.7. Indonesia
17.8. Thailand
17.9. Philippines
17.10. Malaysia
17.11. Singapore
17.12. Vietnam
17.13. Taiwan
17.2. China
17.3. India
17.4. Japan
17.5. Australia
17.6. South Korea
17.7. Indonesia
17.8. Thailand
17.9. Philippines
17.10. Malaysia
17.11. Singapore
17.12. Vietnam
17.13. Taiwan
18. Competitive Landscape
18.1. Market Share Analysis, 2024
18.2. FPNV Positioning Matrix, 2024
18.3. Competitive Analysis
18.3.1. Ionis Pharmaceuticals, Inc.
18.3.2. Akcea Therapeutics, Inc.
18.2. FPNV Positioning Matrix, 2024
18.3. Competitive Analysis
18.3.1. Ionis Pharmaceuticals, Inc.
18.3.2. Akcea Therapeutics, Inc.
List of Figures
FIGURE 1. ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET RESEARCH PROCESS
FIGURE 2. GLOBAL ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 3. GLOBAL ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 4. GLOBAL ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY DRUG TYPE, 2024 VS 2030 (%)
FIGURE 6. GLOBAL ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY DRUG TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 8. GLOBAL ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 10. GLOBAL ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2030 (%)
FIGURE 12. GLOBAL ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY PATIENT TYPE, 2024 VS 2030 (%)
FIGURE 14. GLOBAL ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY PATIENT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY THERAPY LINE, 2024 VS 2030 (%)
FIGURE 16. GLOBAL ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY THERAPY LINE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. GLOBAL ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY DISEASE STAGE, 2024 VS 2030 (%)
FIGURE 18. GLOBAL ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY DISEASE STAGE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. AMERICAS ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 20. AMERICAS ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. UNITED STATES ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 22. UNITED STATES ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. EUROPE, MIDDLE EAST & AFRICA ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 24. EUROPE, MIDDLE EAST & AFRICA ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. ASIA-PACIFIC ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 26. ASIA-PACIFIC ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 27. ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 28. ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET, FPNV POSITIONING MATRIX, 2024
FIGURE 29. ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET: RESEARCHAI
FIGURE 30. ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET: RESEARCHSTATISTICS
FIGURE 31. ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET: RESEARCHCONTACTS
FIGURE 32. ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET: RESEARCHARTICLES
FIGURE 2. GLOBAL ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 3. GLOBAL ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 4. GLOBAL ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY DRUG TYPE, 2024 VS 2030 (%)
FIGURE 6. GLOBAL ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY DRUG TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 8. GLOBAL ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 10. GLOBAL ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2030 (%)
FIGURE 12. GLOBAL ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY PATIENT TYPE, 2024 VS 2030 (%)
FIGURE 14. GLOBAL ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY PATIENT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY THERAPY LINE, 2024 VS 2030 (%)
FIGURE 16. GLOBAL ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY THERAPY LINE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. GLOBAL ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY DISEASE STAGE, 2024 VS 2030 (%)
FIGURE 18. GLOBAL ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY DISEASE STAGE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. AMERICAS ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 20. AMERICAS ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. UNITED STATES ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 22. UNITED STATES ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. EUROPE, MIDDLE EAST & AFRICA ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 24. EUROPE, MIDDLE EAST & AFRICA ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. ASIA-PACIFIC ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 26. ASIA-PACIFIC ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 27. ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 28. ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET, FPNV POSITIONING MATRIX, 2024
FIGURE 29. ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET: RESEARCHAI
FIGURE 30. ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET: RESEARCHSTATISTICS
FIGURE 31. ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET: RESEARCHCONTACTS
FIGURE 32. ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET: RESEARCHARTICLES
List of Tables
TABLE 1. ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, 2018-2024 (USD MILLION)
TABLE 4. GLOBAL ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, 2025-2030 (USD MILLION)
TABLE 5. GLOBAL ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
TABLE 6. GLOBAL ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
TABLE 7. GLOBAL ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 8. GLOBAL ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 9. GLOBAL ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
TABLE 10. GLOBAL ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
TABLE 11. GLOBAL ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY EPLONTERSEN, BY REGION, 2018-2024 (USD MILLION)
TABLE 12. GLOBAL ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY EPLONTERSEN, BY REGION, 2025-2030 (USD MILLION)
TABLE 13. GLOBAL ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY INOTERSEN, BY REGION, 2018-2024 (USD MILLION)
TABLE 14. GLOBAL ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY INOTERSEN, BY REGION, 2025-2030 (USD MILLION)
TABLE 15. GLOBAL ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 16. GLOBAL ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 17. GLOBAL ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 18. GLOBAL ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 19. GLOBAL ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY PRIVATE HOSPITAL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 20. GLOBAL ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY PRIVATE HOSPITAL PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 21. GLOBAL ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY PUBLIC HOSPITAL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 22. GLOBAL ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY PUBLIC HOSPITAL PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 23. GLOBAL ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2024 (USD MILLION)
TABLE 24. GLOBAL ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY HOSPITAL PHARMACY, 2025-2030 (USD MILLION)
TABLE 25. GLOBAL ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 26. GLOBAL ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 27. GLOBAL ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY SPECIALTY PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 28. GLOBAL ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY SPECIALTY PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 29. GLOBAL ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 30. GLOBAL ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 31. GLOBAL ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY CLINICS, BY REGION, 2018-2024 (USD MILLION)
TABLE 32. GLOBAL ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY CLINICS, BY REGION, 2025-2030 (USD MILLION)
TABLE 33. GLOBAL ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY GENERAL CLINICS, BY REGION, 2018-2024 (USD MILLION)
TABLE 34. GLOBAL ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY GENERAL CLINICS, BY REGION, 2025-2030 (USD MILLION)
TABLE 35. GLOBAL ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY SPECIALIST CLINICS, BY REGION, 2018-2024 (USD MILLION)
TABLE 36. GLOBAL ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY SPECIALIST CLINICS, BY REGION, 2025-2030 (USD MILLION)
TABLE 37. GLOBAL ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
TABLE 38. GLOBAL ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY CLINICS, 2025-2030 (USD MILLION)
TABLE 39. GLOBAL ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY HOME HEALTHCARE, BY REGION, 2018-2024 (USD MILLION)
TABLE 40. GLOBAL ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY HOME HEALTHCARE, BY REGION, 2025-2030 (USD MILLION)
TABLE 41. GLOBAL ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY SELF ADMINISTRATION, BY REGION, 2018-2024 (USD MILLION)
TABLE 42. GLOBAL ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY SELF ADMINISTRATION, BY REGION, 2025-2030 (USD MILLION)
TABLE 43. GLOBAL ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY VISITING NURSE SERVICES, BY REGION, 2018-2024 (USD MILLION)
TABLE 44. GLOBAL ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY VISITING NURSE SERVICES, BY REGION, 2025-2030 (USD MILLION)
TABLE 45. GLOBAL ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY HOME HEALTHCARE, 2018-2024 (USD MILLION)
TABLE 46. GLOBAL ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY HOME HEALTHCARE, 2025-2030 (USD MILLION)
TABLE 47. GLOBAL ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
TABLE 48. GLOBAL ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2030 (USD MILLION)
TABLE 49. GLOBAL ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY PRIVATE HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
TABLE 50. GLOBAL ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY PRIVATE HOSPITALS, BY REGION, 2025-2030 (USD MILLION)
TABLE 51. GLOBAL ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY PUBLIC HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
TABLE 52. GLOBAL ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY PUBLIC HOSPITALS, BY REGION, 2025-2030 (USD MILLION)
TABLE 53. GLOBAL ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
TABLE 54. GLOBAL ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
TABLE 55. GLOBAL ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY NURSING HOMES, BY REGION, 2018-2024 (USD MILLION)
TABLE 56. GLOBAL ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY NURSING HOMES, BY REGION, 2025-2030 (USD MILLION)
TABLE 57. GLOBAL ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY ASSISTED LIVING, BY REGION, 2018-2024 (USD MILLION)
TABLE 58. GLOBAL ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY ASSISTED LIVING, BY REGION, 2025-2030 (USD MILLION)
TABLE 59. GLOBAL ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY LONG TERM CARE FACILITIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 60. GLOBAL ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY LONG TERM CARE FACILITIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 61. GLOBAL ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY NURSING HOMES, 2018-2024 (USD MILLION)
TABLE 62. GLOBAL ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY NURSING HOMES, 2025-2030 (USD MILLION)
TABLE 63. GLOBAL ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 64. GLOBAL ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 65. GLOBAL ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY INTRAVENOUS INFUSION, BY REGION, 2018-2024 (USD MILLION)
TABLE 66. GLOBAL ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY INTRAVENOUS INFUSION, BY REGION, 2025-2030 (USD MILLION)
TABLE 67. GLOBAL ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY ORAL ADMINISTRATION, BY REGION, 2018-2024 (USD MILLION)
TABLE 68. GLOBAL ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY ORAL ADMINISTRATION, BY REGION, 2025-2030 (USD MILLION)
TABLE 69. GLOBAL ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY SUBCUTANEOUS INJECTION, BY REGION, 2018-2024 (USD MILLION)
TABLE 70. GLOBAL ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY SUBCUTANEOUS INJECTION, BY REGION, 2025-2030 (USD MILLION)
TABLE 71. GLOBAL ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
TABLE 72. GLOBAL ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY PATIENT TYPE, 2025-2030 (USD MILLION)
TABLE 73. GLOBAL ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY FAMILIAL, BY REGION, 2018-2024 (USD MILLION)
TABLE 74. GLOBAL ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY FAMILIAL, BY REGION, 2025-2030 (USD MILLION)
TABLE 75. GLOBAL ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY WILD TYPE, BY REGION, 2018-2024 (USD MILLION)
TABLE 76. GLOBAL ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY WILD TYPE, BY REGION, 2025-2030 (USD MILLION)
TABLE 77. GLOBAL ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY THERAPY LINE, 2018-2024 (USD MILLION)
TABLE 78. GLOBAL ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY THERAPY LINE, 2025-2030 (USD MILLION)
TABLE 79. GLOBAL ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY FIRST LINE, BY REGION, 2018-2024 (USD MILLION)
TABLE 80. GLOBAL ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY FIRST LINE, BY REGION, 2025-2030 (USD MILLION)
TABLE 81. GLOBAL ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY SECOND LINE, BY REGION, 2018-2024 (USD MILLION)
TABLE 82. GLOBAL ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY SECOND LINE, BY REGION, 2025-2030 (USD MILLION)
TABLE 83. GLOBAL ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY THIRD LINE, BY REGION, 2018-2024 (USD MILLION)
TABLE 84. GLOBAL ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY THIRD LINE, BY REGION, 2025-2030 (USD MILLION)
TABLE 85. GLOBAL ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY DISEASE STAGE, 2018-2024 (USD MILLION)
TABLE 86. GLOBAL ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY DISEASE STAGE, 2025-2030 (USD MILLION)
TABLE 87. GLOBAL ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY EARLY STAGE, BY REGION, 2018-2024 (USD MILLION)
TABLE 88. GLOBAL ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY EARLY STAGE, BY REGION, 2025-2030 (USD MILLION)
TABLE 89. GLOBAL ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY LATE STAGE, BY REGION, 2018-2024 (USD MILLION)
TABLE 90. GLOBAL ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY LATE STAGE, BY REGION, 2025-2030 (USD MILLION)
TABLE 91. GLOBAL ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY PRE SYMPTOMATIC, BY REGION, 2018-2024 (USD MILLION)
TABLE 92. GLOBAL ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY PRE SYMPTOMATIC, BY REGION, 2025-2030 (USD MILLION)
TABLE 93. AMERICAS ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
TABLE 94. AMERICAS ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
TABLE 95. AMERICAS ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 96. AMERICAS ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 97. AMERICAS ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2024 (USD MILLION)
TABLE 98. AMERICAS ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY HOSPITAL PHARMACY, 2025-2030 (USD MILLION)
TABLE 99. AMERICAS ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 100. AMERICAS ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 101. AMERICAS ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
TABLE 102. AMERICAS ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY CLINICS, 2025-2030 (USD MILLION)
TABLE 103. AMERICAS ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY HOME HEALTHCARE, 2018-2024 (USD MILLION)
TABLE 104. AMERICAS ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY HOME HEALTHCARE, 2025-2030 (USD MILLION)
TABLE 105. AMERICAS ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
TABLE 106. AMERICAS ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
TABLE 107. AMERICAS ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY NURSING HOMES, 2018-2024 (USD MILLION)
TABLE 108. AMERICAS ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY NURSING HOMES, 2025-2030 (USD MILLION)
TABLE 109. AMERICAS ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 110. AMERICAS ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 111. AMERICAS ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
TABLE 112. AMERICAS ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY PATIENT TYPE, 2025-2030 (USD MILLION)
TABLE 113. AMERICAS ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY THERAPY LINE, 2018-2024 (USD MILLION)
TABLE 114. AMERICAS ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY THERAPY LINE, 2025-2030 (USD MILLION)
TABLE 115. AMERICAS ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY DISEASE STAGE, 2018-2024 (USD MILLION)
TABLE 116. AMERICAS ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY DISEASE STAGE, 2025-2030 (USD MILLION)
TABLE 117. AMERICAS ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 118. AMERICAS ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 119. UNITED STATES ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
TABLE 120. UNITED STATES ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
TABLE 121. UNITED STATES ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 122. UNITED STATES ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 123. UNITED STATES ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2024 (USD MILLION)
TABLE 124. UNITED STATES ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY HOSPITAL PHARMACY, 2025-2030 (USD MILLION)
TABLE 125. UNITED STATES ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 126. UNITED STATES ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 127. UNITED STATES ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
TABLE 128. UNITED STATES ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY CLINICS, 2025-2030 (USD MILLION)
TABLE 129. UNITED STATES ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY HOME HEALTHCARE, 2018-2024 (USD MILLION)
TABLE 130. UNITED STATES ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY HOME HEALTHCARE, 2025-2030 (USD MILLION)
TABLE 131. UNITED STATES ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
TABLE 132. UNITED STATES ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
TABLE 133. UNITED STATES ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY NURSING HOMES, 2018-2024 (USD MILLION)
TABLE 134. UNITED STATES ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY NURSING HOMES, 2025-2030 (USD MILLION)
TABLE 135. UNITED STATES ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 136. UNITED STATES ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 137. UNITED STATES ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
TABLE 138. UNITED STATES ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY PATIENT TYPE, 2025-2030 (USD MILLION)
TABLE 139. UNITED STATES ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY THERAPY LINE, 2018-2024 (USD MILLION)
TABLE 140. UNITED STATES ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY THERAPY LINE, 2025-2030 (USD MILLION)
TABLE 141. UNITED STATES ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY DISEASE STAGE, 2018-2024 (USD MILLION)
TABLE 142. UNITED STATES ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY DISEASE STAGE, 2025-2030 (USD MILLION)
TABLE 143. UNITED STATES ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY STATE, 2018-2024 (USD MILLION)
TABLE 144. UNITED STATES ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY STATE, 2025-2030 (USD MILLION)
TABLE 145. CANADA ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
TABLE 146. CANADA ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
TABLE 147. CANADA ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 148. CANADA ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 149. CANADA ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2024 (USD MILLION)
TABLE 150. CANADA ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY HOSPITAL PHARMACY, 2025-2030 (USD MILLION)
TABLE 151. CANADA ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 152. CANADA ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 153. CANADA ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
TABLE 154. CANADA ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY CLINICS, 2025-2030 (USD MILLION)
TABLE 155. CANADA ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY HOME HEALTHCARE, 2018-2024 (USD MILLION)
TABLE 156. CANADA ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY HOME HEALTHCARE, 2025-2030 (USD MILLION)
TABLE 157. CANADA ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
TABLE 158. CANADA ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
TABLE 159. CANADA ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY NURSING HOMES, 2018-2024 (USD MILLION)
TABLE 160. CANADA ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY NURSING HOMES, 2025-2030 (USD MILLION)
TABLE 161. CANADA ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 162. CANADA ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 163. CANADA ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
TABLE 164. CANADA ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY PATIENT TYPE, 2025-2030 (USD MILLION)
TABLE 165. CANADA ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY THERAPY LINE, 2018-2024 (USD MILLION)
TABLE 166. CANADA ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY THERAPY LINE, 2025-2030 (USD MILLION)
TABLE 167. CANADA ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY DISEASE STAGE, 2018-2024 (USD MILLION)
TABLE 168. CANADA ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY DISEASE STAGE, 2025-2030 (USD MILLION)
TABLE 169. MEXICO ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
TABLE 170. MEXICO ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
TABLE 171. MEXICO ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 172. MEXICO ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 173. MEXICO ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2024 (USD MILLION)
TABLE 174. MEXICO ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY HOSPITAL PHARMACY, 2025-2030 (USD MILLION)
TABLE 175. MEXICO ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 176. MEXICO ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 177. MEXICO ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
TABLE 178. MEXICO ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY CLINICS, 2025-2030 (USD MILLION)
TABLE 179. MEXICO ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY HOME HEALTHCARE, 2018-2024 (USD MILLION)
TABLE 180. MEXICO ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY HOME HEALTHCARE, 2025-2030 (USD MILLION)
TABLE 181. MEXICO ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
TABLE 182. MEXICO ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
TABLE 183. MEXICO ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY NURSING HOMES, 2018-2024 (USD MILLION)
TABLE 184. MEXICO ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY NURSING HOMES, 2025-2030 (USD MILLION)
TABLE 185. MEXICO ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 186. MEXICO ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 187. MEXICO ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
TABLE 188. MEXICO ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY PATIENT TYPE, 2025-2030 (USD MILLION)
TABLE 189. MEXICO ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY THERAPY LINE, 2018-2024 (USD MILLION)
TABLE 190. MEXICO ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY THERAPY LINE, 2025-2030 (USD MILLION)
TABLE 191. MEXICO ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY DISEASE STAGE, 2018-2024 (USD MILLION)
TABLE 192. MEXICO ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY DISEASE STAGE, 2025-2030 (USD MILLION)
TABLE 193. BRAZIL ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
TABLE 194. BRAZIL ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
TABLE 195. BRAZIL ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 196. BRAZIL ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 197. BRAZIL ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2024 (USD MILLION)
TABLE 198. BRAZIL ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY HOSPITAL PHARMACY, 2025-2030 (USD MILLION)
TABLE 199. BRAZIL ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 200. BRAZIL ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 201. BRAZIL ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
TABLE 202. BRAZIL ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY CLINICS, 2025-2030 (USD MILLION)
TABLE 203. BRAZIL ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY HOME HEALTHCARE, 2018-2024 (USD MILLION)
TABLE 204. BRAZIL ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY HOME HEALTHCARE, 2025-2030 (USD MILLION)
TABLE 205. BRAZIL ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
TABLE 206. BRAZIL ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
TABLE 207. BRAZIL ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY NURSING HOMES, 2018-2024 (USD MILLION)
TABLE 208. BRAZIL ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY NURSING HOMES, 2025-2030 (USD MILLION)
TABLE 209. BRAZIL ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 210. BRAZIL ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 211. BRAZIL ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
TABLE 212. BRAZIL ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY PATIENT TYPE, 2025-2030 (USD MILLION)
TABLE 213. BRAZIL ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY THERAPY LINE, 2018-2024 (USD MILLION)
TABLE 214. BRAZIL ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY THERAPY LINE, 2025-2030 (USD MILLION)
TABLE 215. BRAZIL ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY DISEASE STAGE, 2018-2024 (USD MILLION)
TABLE 216. BRAZIL ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY DISEASE STAGE, 2025-2030 (USD MILLION)
TABLE 217. ARGENTINA ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
TABLE 218. ARGENTINA ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
TABLE 219. ARGENTINA ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 220. ARGENTINA ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 221. ARGENTINA ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2024 (USD MILLION)
TABLE 222. ARGENTINA ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY HOSPITAL PHARMACY, 2025-2030 (USD MILLION)
TABLE 223. ARGENTINA ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 224. ARGENTINA ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 225. ARGENTINA ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
TABLE 226. ARGENTINA ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY CLINICS, 2025-2030 (USD MILLION)
TABLE 227. ARGENTINA ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY HOME HEALTHCARE, 2018-2024 (USD MILLION)
TABLE 228. ARGENTINA ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY HOME HEALTHCARE, 2025-2030 (USD MILLION)
TABLE 229. ARGENTINA ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
TABLE 230. ARGENTINA ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
TABLE 231. ARGENTINA ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY NURSING HOMES, 2018-2024 (USD MILLION)
TABLE 232. ARGENTINA ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY NURSING HOMES, 2025-2030 (USD MILLION)
TABLE 233. ARGENTINA ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 234. ARGENTINA ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 235. ARGENTINA ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
TABLE 236. ARGENTINA ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY PATIENT TYPE, 2025-2030 (USD MILLION)
TABLE 237. ARGENTINA ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY THERAPY LINE, 2018-2024 (USD MILLION)
TABLE 238. ARGENTINA ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY THERAPY LINE, 2025-2030 (USD MILLION)
TABLE 239. ARGENTINA ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY DISEASE STAGE, 2018-2024 (USD MILLION)
TABLE 240. ARGENTINA ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY DISEASE STAGE, 2025-2030 (USD MILLION)
TABLE 241. EUROPE, MIDDLE EAST & AFRICA ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
TABLE 242. EUROPE, MIDDLE EAST & AFRICA ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
TABLE 243. EUROPE, MIDDLE EAST & AFRICA ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 244. EUROPE, MIDDLE EAST & AFRICA ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 245. EUROPE, MIDDLE EAST & AFRICA ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2024 (USD MILLION)
TABLE 246. EUROPE, MIDDLE EAST & AFRICA ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY HOSPITAL PHARMACY, 2025-2030 (USD MILLION)
TABLE 247. EUROPE, MIDDLE EAST & AFRICA ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 248. EUROPE, MIDDLE EAST & AFRICA ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 249. EUROPE, MIDDLE EAST & AFRICA ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
TABLE 250. EUROPE, MIDDLE EAST & AFRICA ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY CLINICS, 2025-2030 (USD MILLION)
TABLE 251. EUROPE, MIDDLE EAST & AFRICA ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY HOME HEALTHCARE, 2018-2024 (USD MILLION)
TABLE 252. EUROPE, MIDDLE EAST & AFRICA ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY HOME HEALTHCARE, 2025-2030 (USD MILLION)
TABLE 253. EUROPE, MIDDLE EAST & AFRICA ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
TABLE 254. EUROPE, MIDDLE EAST & AFRICA ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
TABLE 255. EUROPE, MIDDLE EAST & AFRICA ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY NURSING HOMES, 2018-2024 (USD MILLION)
TABLE 256. EUROPE, MIDDLE EAST & AFRICA ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY NURSING HOMES, 2025-2030 (USD MILLION)
TABLE 257. EUROPE, MIDDLE EAST & AFRICA ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 258. EUROPE, MIDDLE EAST & AFRICA ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 259. EUROPE, MIDDLE EAST & AFRICA ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
TABLE 260. EUROPE, MIDDLE EAST & AFRICA ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY PATIENT TYPE, 2025-2030 (USD MILLION)
TABLE 261. EUROPE, MIDDLE EAST & AFRICA ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY THERAPY LINE, 2018-2024 (USD MILLION)
TABLE 262. EUROPE, MIDDLE EAST & AFRICA ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY THERAPY LINE, 2025-2030 (USD MILLION)
TABLE 263. EUROPE, MIDDLE EAST & AFRICA ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY DISEASE STAGE, 2018-2024 (USD MILLION)
TABLE 264. EUROPE, MIDDLE EAST & AFRICA ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY DISEASE STAGE, 2025-2030 (USD MILLION)
TABLE 265. EUROPE, MIDDLE EAST & AFRICA ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 266. EUROPE, MIDDLE EAST & AFRICA ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 267. UNITED KINGDOM ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
TABLE 268. UNITED KINGDOM ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
TABLE 269. UNITED KINGDOM ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 270. UNITED KINGDOM ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 271. UNITED KINGDOM ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2024 (USD MILLION)
TABLE 272. UNITED KINGDOM ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY HOSPITAL PHARMACY, 2025-2030 (USD MILLION)
TABLE 273. UNITED KI
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, 2018-2024 (USD MILLION)
TABLE 4. GLOBAL ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, 2025-2030 (USD MILLION)
TABLE 5. GLOBAL ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
TABLE 6. GLOBAL ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
TABLE 7. GLOBAL ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 8. GLOBAL ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 9. GLOBAL ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
TABLE 10. GLOBAL ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
TABLE 11. GLOBAL ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY EPLONTERSEN, BY REGION, 2018-2024 (USD MILLION)
TABLE 12. GLOBAL ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY EPLONTERSEN, BY REGION, 2025-2030 (USD MILLION)
TABLE 13. GLOBAL ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY INOTERSEN, BY REGION, 2018-2024 (USD MILLION)
TABLE 14. GLOBAL ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY INOTERSEN, BY REGION, 2025-2030 (USD MILLION)
TABLE 15. GLOBAL ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 16. GLOBAL ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 17. GLOBAL ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 18. GLOBAL ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 19. GLOBAL ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY PRIVATE HOSPITAL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 20. GLOBAL ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY PRIVATE HOSPITAL PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 21. GLOBAL ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY PUBLIC HOSPITAL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 22. GLOBAL ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY PUBLIC HOSPITAL PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 23. GLOBAL ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2024 (USD MILLION)
TABLE 24. GLOBAL ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY HOSPITAL PHARMACY, 2025-2030 (USD MILLION)
TABLE 25. GLOBAL ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 26. GLOBAL ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 27. GLOBAL ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY SPECIALTY PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 28. GLOBAL ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY SPECIALTY PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 29. GLOBAL ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 30. GLOBAL ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 31. GLOBAL ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY CLINICS, BY REGION, 2018-2024 (USD MILLION)
TABLE 32. GLOBAL ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY CLINICS, BY REGION, 2025-2030 (USD MILLION)
TABLE 33. GLOBAL ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY GENERAL CLINICS, BY REGION, 2018-2024 (USD MILLION)
TABLE 34. GLOBAL ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY GENERAL CLINICS, BY REGION, 2025-2030 (USD MILLION)
TABLE 35. GLOBAL ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY SPECIALIST CLINICS, BY REGION, 2018-2024 (USD MILLION)
TABLE 36. GLOBAL ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY SPECIALIST CLINICS, BY REGION, 2025-2030 (USD MILLION)
TABLE 37. GLOBAL ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
TABLE 38. GLOBAL ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY CLINICS, 2025-2030 (USD MILLION)
TABLE 39. GLOBAL ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY HOME HEALTHCARE, BY REGION, 2018-2024 (USD MILLION)
TABLE 40. GLOBAL ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY HOME HEALTHCARE, BY REGION, 2025-2030 (USD MILLION)
TABLE 41. GLOBAL ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY SELF ADMINISTRATION, BY REGION, 2018-2024 (USD MILLION)
TABLE 42. GLOBAL ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY SELF ADMINISTRATION, BY REGION, 2025-2030 (USD MILLION)
TABLE 43. GLOBAL ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY VISITING NURSE SERVICES, BY REGION, 2018-2024 (USD MILLION)
TABLE 44. GLOBAL ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY VISITING NURSE SERVICES, BY REGION, 2025-2030 (USD MILLION)
TABLE 45. GLOBAL ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY HOME HEALTHCARE, 2018-2024 (USD MILLION)
TABLE 46. GLOBAL ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY HOME HEALTHCARE, 2025-2030 (USD MILLION)
TABLE 47. GLOBAL ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
TABLE 48. GLOBAL ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2030 (USD MILLION)
TABLE 49. GLOBAL ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY PRIVATE HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
TABLE 50. GLOBAL ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY PRIVATE HOSPITALS, BY REGION, 2025-2030 (USD MILLION)
TABLE 51. GLOBAL ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY PUBLIC HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
TABLE 52. GLOBAL ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY PUBLIC HOSPITALS, BY REGION, 2025-2030 (USD MILLION)
TABLE 53. GLOBAL ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
TABLE 54. GLOBAL ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
TABLE 55. GLOBAL ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY NURSING HOMES, BY REGION, 2018-2024 (USD MILLION)
TABLE 56. GLOBAL ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY NURSING HOMES, BY REGION, 2025-2030 (USD MILLION)
TABLE 57. GLOBAL ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY ASSISTED LIVING, BY REGION, 2018-2024 (USD MILLION)
TABLE 58. GLOBAL ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY ASSISTED LIVING, BY REGION, 2025-2030 (USD MILLION)
TABLE 59. GLOBAL ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY LONG TERM CARE FACILITIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 60. GLOBAL ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY LONG TERM CARE FACILITIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 61. GLOBAL ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY NURSING HOMES, 2018-2024 (USD MILLION)
TABLE 62. GLOBAL ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY NURSING HOMES, 2025-2030 (USD MILLION)
TABLE 63. GLOBAL ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 64. GLOBAL ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 65. GLOBAL ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY INTRAVENOUS INFUSION, BY REGION, 2018-2024 (USD MILLION)
TABLE 66. GLOBAL ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY INTRAVENOUS INFUSION, BY REGION, 2025-2030 (USD MILLION)
TABLE 67. GLOBAL ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY ORAL ADMINISTRATION, BY REGION, 2018-2024 (USD MILLION)
TABLE 68. GLOBAL ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY ORAL ADMINISTRATION, BY REGION, 2025-2030 (USD MILLION)
TABLE 69. GLOBAL ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY SUBCUTANEOUS INJECTION, BY REGION, 2018-2024 (USD MILLION)
TABLE 70. GLOBAL ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY SUBCUTANEOUS INJECTION, BY REGION, 2025-2030 (USD MILLION)
TABLE 71. GLOBAL ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
TABLE 72. GLOBAL ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY PATIENT TYPE, 2025-2030 (USD MILLION)
TABLE 73. GLOBAL ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY FAMILIAL, BY REGION, 2018-2024 (USD MILLION)
TABLE 74. GLOBAL ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY FAMILIAL, BY REGION, 2025-2030 (USD MILLION)
TABLE 75. GLOBAL ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY WILD TYPE, BY REGION, 2018-2024 (USD MILLION)
TABLE 76. GLOBAL ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY WILD TYPE, BY REGION, 2025-2030 (USD MILLION)
TABLE 77. GLOBAL ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY THERAPY LINE, 2018-2024 (USD MILLION)
TABLE 78. GLOBAL ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY THERAPY LINE, 2025-2030 (USD MILLION)
TABLE 79. GLOBAL ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY FIRST LINE, BY REGION, 2018-2024 (USD MILLION)
TABLE 80. GLOBAL ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY FIRST LINE, BY REGION, 2025-2030 (USD MILLION)
TABLE 81. GLOBAL ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY SECOND LINE, BY REGION, 2018-2024 (USD MILLION)
TABLE 82. GLOBAL ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY SECOND LINE, BY REGION, 2025-2030 (USD MILLION)
TABLE 83. GLOBAL ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY THIRD LINE, BY REGION, 2018-2024 (USD MILLION)
TABLE 84. GLOBAL ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY THIRD LINE, BY REGION, 2025-2030 (USD MILLION)
TABLE 85. GLOBAL ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY DISEASE STAGE, 2018-2024 (USD MILLION)
TABLE 86. GLOBAL ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY DISEASE STAGE, 2025-2030 (USD MILLION)
TABLE 87. GLOBAL ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY EARLY STAGE, BY REGION, 2018-2024 (USD MILLION)
TABLE 88. GLOBAL ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY EARLY STAGE, BY REGION, 2025-2030 (USD MILLION)
TABLE 89. GLOBAL ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY LATE STAGE, BY REGION, 2018-2024 (USD MILLION)
TABLE 90. GLOBAL ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY LATE STAGE, BY REGION, 2025-2030 (USD MILLION)
TABLE 91. GLOBAL ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY PRE SYMPTOMATIC, BY REGION, 2018-2024 (USD MILLION)
TABLE 92. GLOBAL ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY PRE SYMPTOMATIC, BY REGION, 2025-2030 (USD MILLION)
TABLE 93. AMERICAS ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
TABLE 94. AMERICAS ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
TABLE 95. AMERICAS ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 96. AMERICAS ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 97. AMERICAS ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2024 (USD MILLION)
TABLE 98. AMERICAS ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY HOSPITAL PHARMACY, 2025-2030 (USD MILLION)
TABLE 99. AMERICAS ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 100. AMERICAS ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 101. AMERICAS ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
TABLE 102. AMERICAS ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY CLINICS, 2025-2030 (USD MILLION)
TABLE 103. AMERICAS ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY HOME HEALTHCARE, 2018-2024 (USD MILLION)
TABLE 104. AMERICAS ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY HOME HEALTHCARE, 2025-2030 (USD MILLION)
TABLE 105. AMERICAS ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
TABLE 106. AMERICAS ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
TABLE 107. AMERICAS ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY NURSING HOMES, 2018-2024 (USD MILLION)
TABLE 108. AMERICAS ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY NURSING HOMES, 2025-2030 (USD MILLION)
TABLE 109. AMERICAS ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 110. AMERICAS ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 111. AMERICAS ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
TABLE 112. AMERICAS ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY PATIENT TYPE, 2025-2030 (USD MILLION)
TABLE 113. AMERICAS ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY THERAPY LINE, 2018-2024 (USD MILLION)
TABLE 114. AMERICAS ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY THERAPY LINE, 2025-2030 (USD MILLION)
TABLE 115. AMERICAS ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY DISEASE STAGE, 2018-2024 (USD MILLION)
TABLE 116. AMERICAS ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY DISEASE STAGE, 2025-2030 (USD MILLION)
TABLE 117. AMERICAS ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 118. AMERICAS ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 119. UNITED STATES ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
TABLE 120. UNITED STATES ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
TABLE 121. UNITED STATES ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 122. UNITED STATES ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 123. UNITED STATES ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2024 (USD MILLION)
TABLE 124. UNITED STATES ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY HOSPITAL PHARMACY, 2025-2030 (USD MILLION)
TABLE 125. UNITED STATES ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 126. UNITED STATES ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 127. UNITED STATES ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
TABLE 128. UNITED STATES ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY CLINICS, 2025-2030 (USD MILLION)
TABLE 129. UNITED STATES ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY HOME HEALTHCARE, 2018-2024 (USD MILLION)
TABLE 130. UNITED STATES ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY HOME HEALTHCARE, 2025-2030 (USD MILLION)
TABLE 131. UNITED STATES ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
TABLE 132. UNITED STATES ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
TABLE 133. UNITED STATES ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY NURSING HOMES, 2018-2024 (USD MILLION)
TABLE 134. UNITED STATES ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY NURSING HOMES, 2025-2030 (USD MILLION)
TABLE 135. UNITED STATES ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 136. UNITED STATES ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 137. UNITED STATES ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
TABLE 138. UNITED STATES ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY PATIENT TYPE, 2025-2030 (USD MILLION)
TABLE 139. UNITED STATES ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY THERAPY LINE, 2018-2024 (USD MILLION)
TABLE 140. UNITED STATES ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY THERAPY LINE, 2025-2030 (USD MILLION)
TABLE 141. UNITED STATES ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY DISEASE STAGE, 2018-2024 (USD MILLION)
TABLE 142. UNITED STATES ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY DISEASE STAGE, 2025-2030 (USD MILLION)
TABLE 143. UNITED STATES ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY STATE, 2018-2024 (USD MILLION)
TABLE 144. UNITED STATES ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY STATE, 2025-2030 (USD MILLION)
TABLE 145. CANADA ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
TABLE 146. CANADA ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
TABLE 147. CANADA ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 148. CANADA ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 149. CANADA ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2024 (USD MILLION)
TABLE 150. CANADA ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY HOSPITAL PHARMACY, 2025-2030 (USD MILLION)
TABLE 151. CANADA ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 152. CANADA ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 153. CANADA ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
TABLE 154. CANADA ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY CLINICS, 2025-2030 (USD MILLION)
TABLE 155. CANADA ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY HOME HEALTHCARE, 2018-2024 (USD MILLION)
TABLE 156. CANADA ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY HOME HEALTHCARE, 2025-2030 (USD MILLION)
TABLE 157. CANADA ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
TABLE 158. CANADA ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
TABLE 159. CANADA ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY NURSING HOMES, 2018-2024 (USD MILLION)
TABLE 160. CANADA ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY NURSING HOMES, 2025-2030 (USD MILLION)
TABLE 161. CANADA ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 162. CANADA ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 163. CANADA ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
TABLE 164. CANADA ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY PATIENT TYPE, 2025-2030 (USD MILLION)
TABLE 165. CANADA ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY THERAPY LINE, 2018-2024 (USD MILLION)
TABLE 166. CANADA ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY THERAPY LINE, 2025-2030 (USD MILLION)
TABLE 167. CANADA ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY DISEASE STAGE, 2018-2024 (USD MILLION)
TABLE 168. CANADA ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY DISEASE STAGE, 2025-2030 (USD MILLION)
TABLE 169. MEXICO ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
TABLE 170. MEXICO ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
TABLE 171. MEXICO ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 172. MEXICO ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 173. MEXICO ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2024 (USD MILLION)
TABLE 174. MEXICO ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY HOSPITAL PHARMACY, 2025-2030 (USD MILLION)
TABLE 175. MEXICO ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 176. MEXICO ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 177. MEXICO ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
TABLE 178. MEXICO ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY CLINICS, 2025-2030 (USD MILLION)
TABLE 179. MEXICO ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY HOME HEALTHCARE, 2018-2024 (USD MILLION)
TABLE 180. MEXICO ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY HOME HEALTHCARE, 2025-2030 (USD MILLION)
TABLE 181. MEXICO ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
TABLE 182. MEXICO ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
TABLE 183. MEXICO ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY NURSING HOMES, 2018-2024 (USD MILLION)
TABLE 184. MEXICO ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY NURSING HOMES, 2025-2030 (USD MILLION)
TABLE 185. MEXICO ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 186. MEXICO ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 187. MEXICO ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
TABLE 188. MEXICO ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY PATIENT TYPE, 2025-2030 (USD MILLION)
TABLE 189. MEXICO ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY THERAPY LINE, 2018-2024 (USD MILLION)
TABLE 190. MEXICO ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY THERAPY LINE, 2025-2030 (USD MILLION)
TABLE 191. MEXICO ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY DISEASE STAGE, 2018-2024 (USD MILLION)
TABLE 192. MEXICO ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY DISEASE STAGE, 2025-2030 (USD MILLION)
TABLE 193. BRAZIL ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
TABLE 194. BRAZIL ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
TABLE 195. BRAZIL ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 196. BRAZIL ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 197. BRAZIL ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2024 (USD MILLION)
TABLE 198. BRAZIL ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY HOSPITAL PHARMACY, 2025-2030 (USD MILLION)
TABLE 199. BRAZIL ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 200. BRAZIL ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 201. BRAZIL ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
TABLE 202. BRAZIL ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY CLINICS, 2025-2030 (USD MILLION)
TABLE 203. BRAZIL ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY HOME HEALTHCARE, 2018-2024 (USD MILLION)
TABLE 204. BRAZIL ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY HOME HEALTHCARE, 2025-2030 (USD MILLION)
TABLE 205. BRAZIL ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
TABLE 206. BRAZIL ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
TABLE 207. BRAZIL ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY NURSING HOMES, 2018-2024 (USD MILLION)
TABLE 208. BRAZIL ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY NURSING HOMES, 2025-2030 (USD MILLION)
TABLE 209. BRAZIL ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 210. BRAZIL ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 211. BRAZIL ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
TABLE 212. BRAZIL ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY PATIENT TYPE, 2025-2030 (USD MILLION)
TABLE 213. BRAZIL ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY THERAPY LINE, 2018-2024 (USD MILLION)
TABLE 214. BRAZIL ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY THERAPY LINE, 2025-2030 (USD MILLION)
TABLE 215. BRAZIL ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY DISEASE STAGE, 2018-2024 (USD MILLION)
TABLE 216. BRAZIL ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY DISEASE STAGE, 2025-2030 (USD MILLION)
TABLE 217. ARGENTINA ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
TABLE 218. ARGENTINA ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
TABLE 219. ARGENTINA ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 220. ARGENTINA ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 221. ARGENTINA ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2024 (USD MILLION)
TABLE 222. ARGENTINA ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY HOSPITAL PHARMACY, 2025-2030 (USD MILLION)
TABLE 223. ARGENTINA ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 224. ARGENTINA ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 225. ARGENTINA ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
TABLE 226. ARGENTINA ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY CLINICS, 2025-2030 (USD MILLION)
TABLE 227. ARGENTINA ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY HOME HEALTHCARE, 2018-2024 (USD MILLION)
TABLE 228. ARGENTINA ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY HOME HEALTHCARE, 2025-2030 (USD MILLION)
TABLE 229. ARGENTINA ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
TABLE 230. ARGENTINA ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
TABLE 231. ARGENTINA ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY NURSING HOMES, 2018-2024 (USD MILLION)
TABLE 232. ARGENTINA ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY NURSING HOMES, 2025-2030 (USD MILLION)
TABLE 233. ARGENTINA ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 234. ARGENTINA ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 235. ARGENTINA ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
TABLE 236. ARGENTINA ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY PATIENT TYPE, 2025-2030 (USD MILLION)
TABLE 237. ARGENTINA ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY THERAPY LINE, 2018-2024 (USD MILLION)
TABLE 238. ARGENTINA ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY THERAPY LINE, 2025-2030 (USD MILLION)
TABLE 239. ARGENTINA ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY DISEASE STAGE, 2018-2024 (USD MILLION)
TABLE 240. ARGENTINA ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY DISEASE STAGE, 2025-2030 (USD MILLION)
TABLE 241. EUROPE, MIDDLE EAST & AFRICA ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
TABLE 242. EUROPE, MIDDLE EAST & AFRICA ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
TABLE 243. EUROPE, MIDDLE EAST & AFRICA ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 244. EUROPE, MIDDLE EAST & AFRICA ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 245. EUROPE, MIDDLE EAST & AFRICA ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2024 (USD MILLION)
TABLE 246. EUROPE, MIDDLE EAST & AFRICA ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY HOSPITAL PHARMACY, 2025-2030 (USD MILLION)
TABLE 247. EUROPE, MIDDLE EAST & AFRICA ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 248. EUROPE, MIDDLE EAST & AFRICA ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 249. EUROPE, MIDDLE EAST & AFRICA ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
TABLE 250. EUROPE, MIDDLE EAST & AFRICA ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY CLINICS, 2025-2030 (USD MILLION)
TABLE 251. EUROPE, MIDDLE EAST & AFRICA ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY HOME HEALTHCARE, 2018-2024 (USD MILLION)
TABLE 252. EUROPE, MIDDLE EAST & AFRICA ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY HOME HEALTHCARE, 2025-2030 (USD MILLION)
TABLE 253. EUROPE, MIDDLE EAST & AFRICA ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
TABLE 254. EUROPE, MIDDLE EAST & AFRICA ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
TABLE 255. EUROPE, MIDDLE EAST & AFRICA ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY NURSING HOMES, 2018-2024 (USD MILLION)
TABLE 256. EUROPE, MIDDLE EAST & AFRICA ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY NURSING HOMES, 2025-2030 (USD MILLION)
TABLE 257. EUROPE, MIDDLE EAST & AFRICA ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 258. EUROPE, MIDDLE EAST & AFRICA ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 259. EUROPE, MIDDLE EAST & AFRICA ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
TABLE 260. EUROPE, MIDDLE EAST & AFRICA ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY PATIENT TYPE, 2025-2030 (USD MILLION)
TABLE 261. EUROPE, MIDDLE EAST & AFRICA ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY THERAPY LINE, 2018-2024 (USD MILLION)
TABLE 262. EUROPE, MIDDLE EAST & AFRICA ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY THERAPY LINE, 2025-2030 (USD MILLION)
TABLE 263. EUROPE, MIDDLE EAST & AFRICA ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY DISEASE STAGE, 2018-2024 (USD MILLION)
TABLE 264. EUROPE, MIDDLE EAST & AFRICA ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY DISEASE STAGE, 2025-2030 (USD MILLION)
TABLE 265. EUROPE, MIDDLE EAST & AFRICA ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 266. EUROPE, MIDDLE EAST & AFRICA ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 267. UNITED KINGDOM ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
TABLE 268. UNITED KINGDOM ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
TABLE 269. UNITED KINGDOM ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 270. UNITED KINGDOM ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 271. UNITED KINGDOM ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2024 (USD MILLION)
TABLE 272. UNITED KINGDOM ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR MARKET SIZE, BY HOSPITAL PHARMACY, 2025-2030 (USD MILLION)
TABLE 273. UNITED KI
Samples
LOADING...
Companies Mentioned
The companies profiled in this Antisense Oligonucleotides Drugs for ATTR Market report include:- Ionis Pharmaceuticals, Inc.
- Akcea Therapeutics, Inc.
